Nubeqa

News

Chasing rivals, Bayer files Nubeqa for new prostate cancer u...

Bayer has filed for approval to extend the use of its prostate cancer therapy Nubeqa as it tries to achieve labelling parity with rival drugs from Pfizer/Astellas and Johnson & Jonson,

News

Bayer triples sales forecast for prostate cancer drug Nubeqa

Bayer now says it expects to make €3 billion in sales for its prostate cancer treatment Nubeqa, up from an earlier estimate of €1 billion, after reviewing new data for the drug in metastati

News

Trial closes gap between Bayer's Nubeqa and rivals in prosta...

Bayer's Nubeqa is making headway as a treatment for castration-resistant prostate cancer (CRPC), but could be on track to expand its eligible patient population thanks to new phase 3 data.<

Chasing rivals, Bayer files Nubeqa for new prostate cancer u...

Bayer triples sales forecast for prostate cancer drug Nubeqa

Trial closes gap between Bayer's Nubeqa and rivals in prosta...

NHS staff 'feel unprepared for digital transformation'

How to meet your physicians where they are online

Editor's Picks